PT  - JOURNAL ARTICLE
AU  - Zullo, Andrew R.
AU  - Riester, Melissa R.
AU  - Goldberg, Elizabeth M.
AU  - Cupp, Meghan A.
AU  - Berry, Sarah D.
AU  - Beaudoin, Francesca L.
TI  - Differences in Skilled Nursing Facility Characteristics and Quality Ratings by Long-Term Care Pharmacy Provider
AID  - 10.1101/2021.08.31.21262894
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.31.21262894
4099  - http://medrxiv.org/content/early/2021/09/05/2021.08.31.21262894.short
4100  - http://medrxiv.org/content/early/2021/09/05/2021.08.31.21262894.full
AB  - Objectives Limited data exist on the U.S. long-term care (LTC) pharmacy market and how skilled nursing facilities (SNFs) may differ by LTC pharmacy provider. We estimated the market shares of two major LTC pharmacies (Omnicare and PharMerica) and assessed if SNF characteristics differ by pharmacy.Design Cross-sectional.Setting and Participants Seventy-five Rhode Island (RI) SNFs that provided post-acute care (PAC) services in 2019.Methods SNF location, structure, staffing measures, and quality ratings were ascertained from publicly available data sources. The LTC pharmacy used by each SNF was compiled by case managers at a RI health system.Results Among 75 SNFs, 32 (43%) were served by Omnicare and 36 (48%) by PharMerica. LASSO logistic regression and random forest models identified 5 key predictors of SNFs selecting PharMerica over Omnicare: number of skilled beds, total number of beds, nursing hours per resident per day, five-star health inspection rating, and average number of residents per day. In a multivariable regression model including 4 predictors (total number of beds excluded due to collinearity), SNFs had a 6% higher prevalence of using Omnicare over PharMerica for every additional 10 skilled beds (Prevalence Ratio 1.06, 95% CI 1.02-1.10).Conclusions and Implications Omnicare and PharMerica comprised over 90% of the SNF PAC market in RI, with Omnicare covering larger facilities. Understanding if these companies serve a similar proportion of SNFs in other U.S. states is necessary to advance future research initiatives and examine how collaborations between SNFs and LTC pharmacy chains may improve medication management in SNFs.Brief Summary Two pharmacies may comprise over 90% of the skilled nursing facility post-acute care market. This market concentration may represent a prime opportunity to efficiently improve medication management.Competing Interest StatementDr. Zullo receives grant funding paid directly to Brown University for collaborative research on the epidemiology of infections and vaccine use among nursing home residents. Dr. Goldberg served on an advisory panel for TerSera Therapeutics, which examines the use of intravenous cetirizine for the treatment of urticaria. The other authors have no relevant conflicts of interest to disclose.Funding StatementThis study was supported by grant R21AG061632 from the National Institute on Aging. Dr. Zullo was also supported by National Institute on Aging grant R01AG065722. Dr. Goldberg is also supported by grant K76AG059983 from the National Institute on Aging. Dr. Beaudoin is also supported by grants from the Centers for Disease Control and Arnold Ventures.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All datasets were skilled nursing facility-level; therefore, this study did not require Institutional Review Board approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request from the authors.